Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma

Hormone and Metabolic Research

Volumn 44, Issue 5, 2012, Pages 339-342

  Elston, M S ^a   Meyer Rochow, G Y ^b   Holdaway, I ^c   Conaglen, J V ^a  

^a WAIKATO HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c GREEN LANE HOSPITAL   (New Zealand)

Author keywords

c cell carcinoma; catecholamines; hyperparathyroidism; multiple endocrine neoplasia 2A

Indexed keywords

ADRENALIN; ASPARTIC ACID; CALCITONIN; CATECHOLAMINE; METADRENALIN; TYROSINE AMINOTRANSFERASE; VANILMANDELIC ACID;

ADRENAL TUMOR; ADRENALECTOMY; ADULT; ANXIETY; ARTICLE; CALCITONIN BLOOD LEVEL; CASE REPORT; CODON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXON; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HEADACHE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MALE; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARATHYROID GLAND; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RET ONCOGENE; THYROID MEDULLARY CARCINOMA; URINALYSIS;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION, MISSENSE; PEDIGREE; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84858699731     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1295497     Document Type: Article

References (22)

1. Mulligan L M, Kwok J B, Healey C S, Elsdon M J, Eng C, Gardner E, Love D R, Mole S E, Moore J K, Papi L, Ponder M A, Telenius H, Tunnacliffe A, Ponder BA J. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature: 1993; 363 458 460 (Pubitemid 23179393)
2. Donis-Keller H, Dou S, Chi D, Carlson K M, Toshima K, Lairmore T C, Howe J R, Moley J F, Goodfellow P, Wells S A Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet: 1993; 2 851 856 (Pubitemid 23216611)
3. Brandi M L, Gagel R F, Angeli A, Bilezikian J P, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri R G, Libroia A, Lips C J, Lombardi G, Mannelli M, Pacini F, Ponder B A, Raue F, Skogseid B, Tamburrano G, Thakker R V, Thompson N W, Tomassetti P, Tonelli F, Wells S A Jr, Marx S J. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab: 2001; 86 5658 5671 (Pubitemid 33152604)
4. Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf): 2008; 69 81 87 (Pubitemid 351847265)
5. Machens A, Holzhausen H J, Thanh P N, Dralle H. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery: 2003; 134 425 431 (Pubitemid 37215147)
6. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R F, van Amstel HK P, Lips C J, Nishisho I, Takai S I, Marsh D J, Robinson B G, Frank-Raue K, Raue F, Xue F, Noll W W, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy G N, Gharib H, Thibodeau S N, Lacroix A, Frilling A, Ponder BA J, Mulligan L M. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA: 1996; 276 1575 1579 (Pubitemid 26384740)
7. Kloos R T, Eng C, Evans D B, Francis G L, Gagel R F, Gharib H, Moley J F, Pacini F, Ringel M D, Schlumberger M, Wells S A Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid: 2009; 19 565 612
8. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter M M, Hoppner W. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab: 1998; 83 770 774 (Pubitemid 28496443)
9. Burke W. Genetic testing. N Engl J Med: 2002; 347 1867 1875
10. Lips C J. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med: 1998; 243 589 594 (Pubitemid 28312261)
11. Decker R, Peacock M. Update on the Profile of Multiple Endocrine Neoplasia Type 2a RET Mutations. Cancer Suppl: 1997; 80 557 568
12. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg: 2004; 28 1271 1274 (Pubitemid 40941291)
13. Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg: 2009; 250 305 310
14. Bae S J, Kim D J, Kim J Y, Park S Y, Choi S H, Song Y D, Ki C S, Chung J H. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A. Thyroid: 2006; 16 609 614 (Pubitemid 44066269)
15. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, Corvol J C, De Keyzer Y, Luton J P, Plouin P F, Bertagna X. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab: 1995; 80 2063 2068
16. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet: 1998; 43 101 106 (Pubitemid 128508963)
17. Asai N, Iwashita T, Murakami H, Takanari H, Ohmori K, Ichihara M, Takahashi M. Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma. Biochem Biophys Res Commun: 1999; 255 587 590 (Pubitemid 29294842)
18. Yao B, Liu X, Liang H, Dong T T, Huang Z M, Chen X, Weng J P. A novel mutation (D631del) of the RET gene was associated with MEN2A in a Chinese pedigree. Endocr J: 2009; 56 99 104
19. Eisenhofer G, Timmers H J, Lenders J W, Bornstein S R, Tiebel O, Mannelli M, King K S, Vocke C D, Linehan W M, Bratslavsky G, Pacak K. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab: 2011; 96 375 384
20. Lenders J W, Pacak K, Walther M M, Linehan W M, Mannelli M, Friberg P, Keiser H R, Goldstein D S, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA: 2002; 287 1427 1434 (Pubitemid 34250506)
21. Modigliani E, Vasen H M, Raue K, Dralle H, Frilling A, Gheri R G, Brandi M L, Limbert E, Niederle B, Forgas L, Rosenberg-Bourgin M, Calmettes C. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med: 1995; 238 363 367
22. Shirkhedkar D. Men and paragangliomas. Endocrine Society of Australia clinical weekend. Hunter Valley, NSW, Australia: 2004